Does intravenous heparin or time-to-treatment/reperfusion explain differences between GUSTO and ISIS-3 results?
J L
JL
Anderson
L A
LA
Karagounis
D002986:Clinical Trials as Topic; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D013300:Streptokinase / Q000627:therapeutic use*; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator